Database

Startups

Main Industry
Health Care
Main Product/Service
The company’s pipeline features novel therapeutic candidates, such as precision-engineered exosomes for targeted drug delivery and nanometer-scale trispecific antibodies that engage T cells. These next-generation biologics are designed to improve the spec
Founded Year
2021
Unified Business No.
90841519
Status
Active
Number of Employees
0
Total Paid-in Capital
498,000,000 (NT$)
Location of Company
Taiwan , Taichung City
Exit Status
Emerging Stock Exchange(2022)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
The company has developed a series of first-in-human novel drugs that are based on the innovative technology platforms of “targeted exosome for drug delivery” and “trispecific T-cell engager antibody”. The Company has various technical patents for the exo



More ↓

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

CALGENT BIOTECHNOLOGY CO., LTD.

Calgent’s drug pipeline includes several novel therapeutic candidates. Their lead asset, CAL056 (Hectinib), is an oral first‑in‑class HECT-domain E3 ubiquitin ligase inhibitor for the treatment of multiple myeloma, which has received Orphan Drug Designati

AltruBio Taiwan Inc.

AltruBio’s lead drug candidates are PSGL-1 agonist antibodies serving as immune checkpoint enhancers: ALTB-168, their first-generation molecule, has demonstrated safety and efficacy in Phase 1 and Phase 2 trials; and the next-generation ALTB-268, a tetrav